T

TCR2 Therapeutics Inc
F:2K7

Watchlist Manager
TCR2 Therapeutics Inc
F:2K7
Watchlist
Price: 1.442 EUR 3.07% Market Closed
Market Cap: 56.6m EUR

Relative Value

There is not enough data to reliably calculate the relative value of 2K7.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

2K7 Relative Value
Base Case
Not Available
T
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.2
vs History
vs Industry
Median 3Y
-0.4
Median 5Y
-0.4
Industry
24.2
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-0.6
Industry
23
vs History
vs Industry
Median 3Y
-0.5
Median 5Y
-0.5
Industry
25.5
vs History
vs Industry
Median 3Y
0.6
Median 5Y
0.6
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
vs History
vs Industry
Median 3Y
0.4
Median 5Y
0.4
Industry
6.1
vs History
vs Industry
Median 3Y
0.4
Median 5Y
0.4
Industry
6.6
vs History
vs Industry
Median 3Y
0.4
Median 5Y
0.4
Industry
8.8
vs History
vs Industry
Median 3Y
0.4
Median 5Y
0.4
Industry
6.8
vs History
vs Industry
Median 3Y
-1.4
Median 5Y
-1.4
Industry
5.7

Multiples Across Competitors

2K7 Competitors Multiples
TCR2 Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
TCR2 Therapeutics Inc
F:2K7
56.6m EUR 0 -0.4 0.3 0.3
IL
Can Fite Biopharma Ltd
TASE:CANF
159.8T ILS 57 882 330.4 -3 974 986 -3 900 678.1 -3 891 995.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 067 817 -161 919.3 -196 621.7 -194 378
US
Abbvie Inc
NYSE:ABBV
389.4B USD 6.5 165.8 16.1 22.9
US
Amgen Inc
NASDAQ:AMGN
173.9B USD 4.8 24.8 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
150.5B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.7B USD 10 32 23.5 24.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.9 -527.7 -574.6 -559.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
84.6B USD 5.9 18.5 17.7 20
AU
CSL Ltd
ASX:CSL
84.8B AUD 3.6 18.9 12.7 15.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.1B USD 15 1 104 148.8 180.4
P/S Multiple
Revenue Growth P/S to Growth
US
T
TCR2 Therapeutics Inc
F:2K7
Average P/S: 9 195 226.6
Not Available
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
57 882 330.4
140%
413 445.2
FR
Pharnext SCA
OTC:PNEXF
34 067 817
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
2 067.9
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.9
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15
46%
0.3
P/E Multiple
Earnings Growth PEG
US
T
TCR2 Therapeutics Inc
F:2K7
Average P/E: 197.5
Negative Multiple: -0.4
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 974 986 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 919.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
165.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
10%
1.8
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 104
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
T
TCR2 Therapeutics Inc
F:2K7
Average EV/EBITDA: 31.2
0.3
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 900 678.1 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 621.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
148.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
T
TCR2 Therapeutics Inc
F:2K7
Average EV/EBIT: 36.8
0.3
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 891 995.3 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 378 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
20
13%
1.5
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
180.4
N/A N/A